Skip to Content
Cancer Diagnosis Program (CDP)
Last Updated: 06/02/16

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)

Posted date: April 5, 2016; Expiration date: June 23, 2017
Application receipt dates: June 22, 2016; June 22 2017, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development due to tissue biopsy biospecimen preanalytical variability. The program will tie in with current efforts to optimize clinical biomarker assays utilized in NCI-sponsored clinical trials. Results from this research program will improve the understanding of how biopsy collection, processing, and storage procedures may affect all aspects of analytical performance for current and emerging clinical biomarkers, as well as expedite clinical biomarker assay development through the evidence-based standardization of biopsy handling practices. Critical information gained through these research awards may increase the reliability of clinical biomarker assays, reduce time requirements for assay development, and decrease assay failure during late-stage testing.

CDP contact: Dr. Abhi Rao, 240-276-5715, abhi.rao@mail.nih.gov

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-15-095 (UH2/UH3)

Posted date: January 21, 2015; Expiration date: October 7, 2017
Application receipt dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is a phased initiative to improve the development of molecular diagnostics for use in NCI-supported clinical trials in cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay.

CDP contact: Dr. Tracy Lively, 240-276-5944, Livelyt@mail.nih.gov

Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-16-056 (U10)

Posted Date: December 10, 2015; Expiration Date: October 7, 2017
Letter of Intent due dates: 30 days prior to the application due date
Application due dates: February 29, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that has essentially completed analytical validation in human samples and whose importance is well justified for development into a clinical assay. Revisions may support acquisition of specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Projects proposed for this FOA require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff.

CDP contacts: Dr. Magdalena Thurin thurinm@mail.nih.gov for assays involving immunological diagnostics and non-companion diagnostics for treatment trials and Dr. Tracy Lively livelyt@mail.nih for response, safety, resistance and risk stratification markers for treatment trials.

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-15-096 (UH3)

Posted date: January 21, 2015; Expiration Date: October 7, 2017
Application receipt dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

CDP contact: Dr. Tracy Lively, 240-276-5944, Livelyt@mail.nih.gov

Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) PAR-13-169

Release/Posted date: April 5, 2013; Expiration date: May 8, 2016
Application receipt dates: February 5, June 5, October 5

This FOA encourages applications from research partnerships formed by academic and industrial investigators. The partnerships should establish an inter-disciplinary research team to work in strategic alliance to develop and translate in vivo imaging systems or support reference methods required to validate in vivo imaging systems on a targeted cancer problem.

Contact: Dr. Houston Baker, CIP, 240-276-5908, bakerhou@mail.nih.gov;
Dr. James A. Deye, 240-276-5690, deyej@mail.nih.gov or
Mr. Miguel R. Ossandon, 240-276-5680, ossandom@mail.nih.gov

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems.

CDP contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]: PA-16-040 (R21)

Release/Posted Date: November 20, 2015; Expiration date: January 8, 2019
Application Receipt Dates: February 16, June 16, October 16

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

Bioengineering Research Grants [BRG]: PAR-13-137 (R01)

Release/Posted Date: October 14, 2009; Expiration date: May 8, 2016 (Pending Renewal)
Application Receipt Dates: February 5, June 5, October 5

The BRGs support multi-disciplinary research performed in in a single laboratory or by multiple organizations. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

Bioengineering Research Partnerships [BRP]: PA-16-116 (U01)

Release/Posted Date: March 2, 2016; Expiration date: January 8, 2019
Application Receipt Dates: May 18, 2016, September 13, 2016, May 18, 2017, September 13, 2017, May 8, 2018, September 13, 2018

The BRPs support large basic, applied, and translational multi-disciplinary research performed by multiple organizations that applies an integrative approach, which includes bioengineering and biomedical/clinical components.

The NCI Innovative Molecular Analysis Technologies (IMAT) Program (http://innovation.cancer.gov/)

Release/Posted date: December 9, 2015; Expiration date: September 27, 2016
Application due date(s): February 26, 2016; May 26, 2016; September 26, 2016

IMAT supports the development of next-generation analytical methodologies and tools that have the potential to revolutionize cancer research, prevention, detection, diagnostics and treatment. The IMAT program funds research in four areas:

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research: RFA-CA-16-001 (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative molecular or cellular analysis technologies for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer.

CDP contact: Dr. Brian Sorg, 240-276-5712, sorgbs@mail.nih.gov

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research: RFA-CA-16-002 (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the advanced development of emerging molecular or cellular analysis technologies for basic or clinical cancer research. This FOA solicits R33 applications where proof-of-principle for the emerging technology or methodology has been provided with supportive preliminary data demonstrating a novel capability for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will not be reviewed.

CDP contact: Dr. Brian Sorg, 240-276-5712, sorgbs@mail.nih.gov

Innovative Technologies for Cancer-Relevant Biospecimen Science: RFA-CA-16-003 (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of technologies that improve the quality of the samples used for cancer research or clinical care. This includes innovative technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

CDP contact: Dr. Rodrigo Chuaqui, 240-276-5910, chuaquir@mail.nih.gov

Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science: RFA-CA-16-004 (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the advanced development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. This FOA solicits R33 applications where proof-of-principle for the emerging technology or methodology has been provided with supportive preliminary data demonstrating a novel capability for maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this FOA and will not be reviewed.

CDP contact: Dr. Rodrigo Chuaqui, 240-276-5910, chuaquir@mail.nih.gov

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm

National Institutes of Health
U.S. Department of Health and Human Services